(Diphtheria + pertussis + tetanus) vaccine is under clinical development by Chongqing Zhifei Biological Products and currently in Phase III for Diphtheria. According to GlobalData, Phase III drugs for Diphtheria have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Diphtheria + pertussis + tetanus) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Diphtheria + pertussis + tetanus) vaccine overview
Vaccine candidate is under development for the prevention of diphtheria, pertussis, and tetanus. The vaccine consists of a mixture of diphtheria, pertussis, and tetanus antigens. It is administered through intramuscular route.
Chongqing Zhifei Biological Products overview
Chongqing Zhifei Biological Products (Zhifei Biological) is a manufacturer of vaccine products. It carries out the research and development production and sales of vaccines and biological products. Its vaccine portfolio includes Haemophilus influenza type-B conjugate vaccine, meningococcal group A and B polysaccharide vaccine, meningococcal group A and C conjugate vaccine, meningococcal groups A and C Haemophilus b conjugate vaccine. The company also offers human papillomavirus, valent pneumococcal polysaccharide, quadrivalent human papillomavirus and oral pentavalent reassortant rotavirus live attenuated vaccines, among others. Zhifei Biological also provides cold chain storage and transportation. It markets its vaccines under the brands Vikant, Gardash, Newmofa, GARDASIL, Leerde and Vaccae. Zhifei Biological is headquartered in Chongqing, Chongqing, China.
For a complete picture of (Diphtheria + pertussis + tetanus) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
